Biotechnological and biosimilar drugs: The process is the product;Biotecnológicos y biosimilares: El proceso es el producto

Atencion Farmaceutica

Volumn 9, Issue 6, 2007, Pages 358-364

  Perayre Badia, M ^a   Leiva Badosa, E ^a   Jodar Masanes R ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Biopharmaceuticals; Biosimilars; Biotechnologicals; Immunogenicity; Pharmacosurveillance

Indexed keywords

BIOLOGICAL PRODUCT;

BIOTECHNOLOGY; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; IATROGENIC DISEASE; IMMUNOGENICITY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PHYSICIAN; PRESCRIPTION; REVIEW;

EID: 41149090136     PISSN: 11397357     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Committee for medicinal products for human use. Guideline on similar biological medicinal products. CHMP/437/04 2005.
2. Domínguez-Gil Hurlé A. Medicamentos biosimlares. Libro de ponencias del LII Congreso Nacional de la SEFH 2007; 49-52.
3. The Economic impact of new biotechnological agents: how does it affect the pharmaceutical expenditure?. 10th Congress of the European Association of Hospital Pharmacists, Lisbon, Portugal, March 2005.
4. Satellite symposium report: Biosimilars: How similar are they?. EJHP 2005; 3: 23-5.
5. Tredree R. The supply chain for biopharmaceuticals: maintaining the correct temperature. EJHP 2007; 13: 52-4.
6. Roger S, Mikhail A. Biosimlars: Opportunity or Cause for Concern?. J Pharm Pharmaceut Sci 2007; 10: 405-10.
7. Covic A, Kuhlmann MK. Biosimilars: recent developments. Int Urol Nephrol 2007; 39: 261-6.
8. Crommelin D, Bermejo T, Bissig M et al. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular-weight pharmaceuticals. EJHP 2005; 11: 11-7.
9. Domínguez-Gil Hurlé A. Los biosimilares llegan a Europa. Economia de la Salud 2007; 6: 82-6.
10. EMEA/CHMP/42832/05. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: Non-clinical and Clinical Issues (CHMP adopted Feb 2006).
11. EMEA/CHMP/BWP/49348/05. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: Quality issues (CHMP adopted Feb 2006).
12. EMEA/CHMP/32775/05. Annex Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: Non-clinical and Clinical Issues-Guidance on similar medicinal products containing recombinant Human Insulin (CHMP adopted Feb 2006).
13. EMEA/CHMP/94526/05. Annex Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: Non-clinical and Clinical Issues-Guidance on similar medicinal products containing recombinant Erythropoietins (CHMP adopted March 2006).
14. EMEA/CHMP/94528/05. Annex Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: Non-clinical and Clinical Issues-Guidance on similar medicinal products containing Somatropin (CHMP adopted Feb 2006).
15. EMEA/CHMP/31329/05. Annex Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: Non-clinical and Clinical Issues-Guidance on similar medicinal products containing recombinant Granulocyte-Colony Stimulating Factor (CHMP adopted Feb 2006).
16. Mikhail A. Legal and regulatory issues in licensing biosimilars. EJHP 2007; 13: 56-9.
17. BOE núm.239: 17420 Orden SCO/2874/2007, 28 septiembre. Ministerio Sanidad y Consumo.